GeoCities knows or has reason to know is failing to delete the information upon request. GeoCities must also provide consumers with a reasonable and secure means to access the information that GeoCities previously collected from them.

Part VII permits GeoCities to retain certain personally identifiable information in its ''archived database'' for the limited purposes of site maintenance, computer file back-up, blocking a child's attempt to register without parental consent, or to respond to requests for such information from law enforcement agencies or pursuant to judicial process. GeoCities must disclose its retention of information in the archived database in its privacy notice.

Part VIII is a consumer education provision. It requires that for five years GeoCities place a clear and prominent hyperlink within its privacy notice directing visitors to the FTC's Web site to view educational material on consumer privacy. Currently, the FTC site contains a brochure entitled: ''Site-Seeing on the Internet,'' which can be found at www.ftc.gov/bcp/conline/pubs/online/sitesee/index.html.

Part IX outlines GeoCities' recordkeeping requirements under the proposed order. Part X requires GeoCities to deliver a copy of the order to certain company officers and personnel. Part XI requires GeoCities to establish an ''information practices training program'' for employees and GeoCities Community Leaders, volunteers who provide a variety of services to GeoCities' members. The program must include training about GeoCities' privacy policies, information security procedures, and disciplinary procedures for violations of its privacy policies.

Parts XII and XIII require GeoCities to notify the Commission of any change in its corporate structure that might affect compliance with the order; and to file compliance reports with the Commission. Part XIV is a ''sunset'' provision, dictating that the order will terminate in twenty years absent certain circumstances.

The purpose of this analysis is to facilitate public comment on the proposed order. It is not intended to constitute an official interpretation of the agreement and proposed order or to modify in any way their terms.

By direction of the Commission.

Benjamin I. Berman,

Acting Secretary.

[FR Doc. 98–22444 Filed 8–19–98; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Translation Advisory Committee for Diabetes Prevention and Control Programs: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Translation Advisory Committee for Diabetes Prevention and Control Programs.

Time and Dates: 9 a.m–6 p.m., September 1, 1998. 9 a.m.–1 p.m., September 2, 1998.

Place: The Holiday Inn Select, 130 Clairmont Avenue, Decatur, Georgia 30030, telephone 404/371–0204.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 50 people.

Purpose: This committee is charged with advising the Director, CDC, regarding policy issues and broad strategies for diabetes translation activities and control programs designed to reduce risk factors, health services utilization, costs, morbidity, and mortality associated with diabetes and its complications. The Committee identifies research advances and technologies ready for translation into widespread community practice; recommends broad public health strategies to be implemented through public health interventions; identifies opportunities for surveillance and epidemiologic assessment of diabetes and related complications; and for the purpose of assuring the most effective use and organization of resources, maintains liaison and coordination of programs with the Federal, voluntary, and private sectors involved in the provision of services to people with diabetes.

Matters to be Discussed: Agenda items include a discussion of public health issues pertinent to the role of behavioral research for diabetes mellitus in the Division of Diabetes Translation (DDT) priorities.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Margaret Hurd, Committee Management Specialist, DDT, National Center for Chronic Disease Prevention and Health Promotion, CDC, 4770 Buford Highway, NE M/S K–10, Atlanta, Georgia 30341–3717, telephone 770/488–5505.

Dated: August 14, 1998.

John C. Burckhardt,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98–22396 Filed 8–19–98; 8:45 am]

BILLING CODE 4163–18–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

FDA Cares About Consumers: A Conversation With America; District Consumer Forum

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of meeting.

The Food and Drug Administration (FDA's), Office of Regulatory Affairs, Southeast Region, Atlanta District Office, and the Office of Consumer Affairs are announcing a district consumer forum entitled ''FDA Cares About Consumers: A Conversation With America.'' This forum will provide an opportunity for consumers, community-based organizations, and other interested stakeholders to participate in open discussions on health issues and agency regulatory actions with FDA officials and tour the new FDA regional laboratory.

Date and Time: The forum will be held on Wednesday, September 16, 1998, from 10 a.m. to 12:30 p.m., with tours of the Southeast Regional Laboratory from 8:30 a.m. to 10 a.m., and 12:30 p.m. to 2:30 p.m.

Location: The forum will be held at the U.S. Food and Drug Administration, The Atlanta Complex, 60 Eighth St. NE., Atlanta, GA 30309.

Contact: JoAnn M. Pittman, Food and Drug Administration, Atlanta District Office, Office of Regulatory Affairs, 60 Eighth St. NE., Atlanta, GA 30309, 404–347–7355.

Registration: Send registration information (including name, title, firm name, address, telephone, and fax number) to Priscilla G. McDaniel, 404–347–4344, FAX 404–347–1912. There is no registration fee for this forum. Space is limited, therefore, interested parties are encouraged to register early. Indicate whether you would like a tour of the laboratory facility and the time you would like the tour. Tour space is very limited and will be filled on a ''first come, first serve basis.''

Transcripts: Transcripts of the forum may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, 5600 Fishers Lane, rm. 12A–16, Rockville,

MD 20857, approximately 15 working days after the forum, at a cost of 10 cents per page.

Dated: August 11, 1998.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 98–22392 Filed 8–19–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98N–0339]

Public Meeting on Section 406(b) of the FDA Modernization Act of 1997

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of meeting.

The Food and Drug Administration (FDA) is announcing the following meeting: Public Meeting on Section 406(b) of the FDA Modernization Act of 1997 (FDAMA). The topic to be discussed is how FDA can best meet its statutory obligations under the Federal Food, Drug, and Cosmetic Act (the act). The meeting is intended to involve participants from consumer and patient advocacy groups, health professionals, scientific and academic experts, and the regulated industry in drafting FDA's developmental plan to meet the objectives of FDAMA.

Date and Time: The meeting will be held on Monday, September 14, 1998, 9 a.m. to 5 p.m.

Location: The meeting will be held at Bethesda Holiday Inn, 8120 Wisconsin Ave., Bethesda, MD 20814.

Contact: Patricia M. Kuntze, Office of External Affairs (HF–60), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–3363, FAX 301–594–0113, or e-mail ''PKuntze@bangate.fda.gov''.

Registration and Requests for Oral Presentations: Send registration information (including name, title, firm name, address, telephone, and fax number), and written material and requests to make oral presentations, to the contact person by Monday, August 31, 1998.

If you need special accommodations due to a disability, please contact Patricia M. Kuntze at least 7 days in advance.

SUPPLEMENTARY INFORMATION:

I. Background

Under section 406(b) of FDAMA, the agency is required to consult with its external stakeholders, specifically ''appropriate scientific and academic experts, health care professionals, representatives of patient and consumer advocacy groups, and the regulated industry.'' Following these consultations, FDA is to develop and publish a plan for achieving compliance with each of its statutory obligations.

Section 406(b) of FDAMA further requires that the plan, which must be published in the **Federal Register** by November 21, 1998, should address, but may not be confined to, the following six objectives: (1) Maximizing the availability and clarity of information about the agency application and submission review processes; (2) maximizing the availability and clarity of information for consumers and patients concerning new products; (3) implementing inspection and postmarket monitoring provisions of the act; (4) assuring access to the scientific and technical expertise needed to carry out FDA's obligations; (5) establishing mechanisms, by July 1, 1999, for meeting specified time periods for the review of applications and submissions; and (6) eliminating backlogs in the review of applications and submissions.

The agency held a series of public meetings to obtain public views on how FDA can best meet its statutory obligations related to foods, biologics, human drugs, medical devices, and veterinary medicine. FDA also solicited specific suggestions on how the agency can most effectively achieve the six FDAMA objectives outlined above. The views received by the agency on these topics were used as a source for identifying crosscutting issues, themes, and priorities that should be addressed in the FDA plan.

This meeting will focus on these crosscutting issues, themes, and priorities. Of particular interest to the agency are its stakeholder views on FDA's consumer health protection obligations and the approaches that should be used to fulfill them. These obligations include: (1) Conducting the research, or taking other steps, necessary to assess risks associated with product consumption/use; (2) establishing standards, based on risk assessment, for products and the processes necessary to produce them; (3) reviewing new product applications and determining the product's acceptability for entry onto the market; (4) assisting new product sponsors in designing and implementing research and testing protocols that will facilitate the progress of their applications through the FDA review process; (5) determining ''experience'' with products once they are on the market; (6) conducting inspections to determine the state of industry compliance with FDA standards; (7) carrying out a variety of strategies to ensure compliance, including education, technical assistance, and more directed enforcement activities such as warning letters, product seizures, and prosecutions; and (8) educating consumers and health professionals on risks and risk-avoidance behavior.

The agency is open to all views and ideas about what methods should be used to carry out these basic consumer protection functions, the level of consumer protection that will be provided by different methods and whether this level of protection is acceptable, and what will be needed to reach the desired level of consumer protection by using the proposed method. To help clarify stakeholder views on FDA's role and approaches for fulfilling its consumer protection obligations, the agency requests that oral and/or written views address the following seven questions:

1. Should the above-listed consumer protection functions be modified in any way? If so, what functions would you change, add, or delete?

2. For which of the above-listed functions do you believe that it would be acceptable for FDA to charge fees?

3. For which of the above-listed functions could, and should, FDA rely more on the efforts of third parties, such as testing laboratories, health professional organizations, standard setting organizations, States, or regulated industry?

4. For which of the above-listed functions do you see the best potential for FDA to collaborate with its external stakeholders, such as States, industry, other regulatory agencies, international organizations, etc. to the greater benefit of all parties?

5. Which of the above-listed functions do you believe offers the greatest opportunities for FDA to place more emphasis on non-regulatory approaches—such as education, technical assistance, and collaborative problem solving—to protect and promote the public health?

6. FDA's product and process standards have long been considered as the ''benchmark'' by which to judge the safety, quality, and efficacy of foods, drugs, biologicals, and medical devices. Would it be appropriate for the agency to sanction the use of an FDA seal or mark on products that meet the 'gold' standard, as a way of encouraging more widely behavior that meets the standard? Should FDA charge user fees to third parties and others who use the seal, as a way of financing agency operations?